Noldoxen (Naloxone Hydrochloride, Oxycodone Hydrochloride)

Oxycodone activates mu‑opioid receptors in the brain and spinal cord, decreasing the transmission of pain signals and producing analgesia. Naloxone, when taken orally, remains largely confined to the gut where it blocks opioid receptors, preventing the constipating effect of oxycodone and lowering the potential for abuse if the tablet is altered.

The specific dose of Noldoxen is individualized by the prescribing healthcare professional based on the patient’s pain intensity, previous opioid exposure, renal and hepatic function, and overall clinical condition. No fixed dosing regimen is provided here; the prescriber will select the appropriate strength and frequency according to medical judgment.

Noldoxen is classified as pregnancy category C, indicating that risk to the fetus cannot be ruled out and the drug should only be used if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; therefore, clinicians should assess the risk‑benefit ratio before prescribing to nursing mothers.

To request Noldoxen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will ask for trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Standard oxycodone provides potent analgesia but is frequently associated with opioid‑induced constipation. Noldoxen adds naloxone, which antagonizes opioid receptors in the gastrointestinal tract, thereby reducing constipation without compromising pain relief. This combination also lowers the abuse potential compared with oxycodone monotherapy, offering a safety advantage for long‑term opioid therapy.

Noldoxen should be stored below 25 °C in a dry environment. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in a bathroom or near a heat source, and keep out of reach of children.

Noldoxen is taken orally, usually as a whole tablet. It should be swallowed with a full glass of water and may be taken with or without food, as directed by the prescriber. The exact timing and frequency are determined by the treating physician based on the individual’s pain management plan.

The most serious risks include respiratory depression, severe hypotension, allergic reactions such as anaphylaxis, and opioid withdrawal syndrome if naloxone precipitates abrupt antagonism. Patients should be monitored closely for signs of breathing difficulty, sudden drops in blood pressure, rash, or withdrawal symptoms, and seek immediate medical attention if they occur.

Noldoxen is contraindicated in individuals with known hypersensitivity to oxycodone, naloxone, or any component of the formulation. It should also be avoided in patients who have taken monoamine oxidase inhibitors within the past 14 days, as well as in those with severe respiratory depression, paralytic ileus, or uncontrolled asthma without appropriate medical supervision.